Bristol-Myers Squibb Company (BMY)
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.63 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.8 per share a year ago.
Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.
While total revenue grew in the quarter, competition weighed on the drugmaker's legacy portfolio.
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.
Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks
Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry's gain of 4.8%.
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
Bristol Myers Squibb: Value Emerges From Distress
Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses from Eliquis and Opdivo expirations, supporting a moderate long-term revenue CAGR. Current valuations reflect excessive pessimism, trading at a 25% discount to BMY's five-year average, with downside risk already priced in.
Bristol Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.
